Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Long-Term Debt Repayments (2016 - 2018)

Amicus Therapeutics filings provide 5 years of Long-Term Debt Repayments readings, the most recent being -$218000.0 for Q4 2018.

  • On a quarterly basis, Long-Term Debt Repayments fell 327.08% to -$218000.0 in Q4 2018 year-over-year; TTM through Dec 2021 was -$218000.0, a 53.52% decrease, with the full-year FY2023 number at $408.0 million, changed N/A from a year prior.
  • Long-Term Debt Repayments hit -$218000.0 in Q4 2018 for Amicus Therapeutics, down from $76000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $96000.0 in Q4 2017 to a low of -$218000.0 in Q4 2018.
  • Median Long-Term Debt Repayments over the past 3 years was $71000.0 (2016), compared with a mean of $45400.0.
  • Biggest five-year swings in Long-Term Debt Repayments: rose 28.0% in 2017 and later crashed 327.08% in 2018.
  • Amicus Therapeutics' Long-Term Debt Repayments stood at $75000.0 in 2016, then rose by 28.0% to $96000.0 in 2017, then tumbled by 327.08% to -$218000.0 in 2018.
  • The last three reported values for Long-Term Debt Repayments were -$218000.0 (Q4 2018), $76000.0 (Q3 2018), and $71000.0 (Q2 2018) per Business Quant data.